Ryanair boss considers increasing staff bonus to tackle excess baggage ‘scourge'
The airline currently pays staff around 1.50 euros (£1.30) for intercepting customers who are bringing bags on to the aircraft.
It is reported that the bonus is capped at about 80 euros (£70) for each staff member per month.
Passengers are charged a fee of up to 75 euros (£65) for bringing luggage that is larger than they paid for while booking their journey.
Ryanair currently includes a small carry-on bag – capped at a size of 40x20x25cm and weight of 10kg – with every ticket.
Passengers must pay a fee if they want to bring larger luggage, or if they want to bring multiple bags.
Ryanair boss Michael O'Leary said on Monday that summer fares would, on average, be the same rate as 2023 – but added that he expects a boost in profitability for the airline by 'controlling costs'.
Members of the European Parliament are pushing for airlines to allow passengers to be allowed to bring on free an on-board personal item and small hand luggage.
However, Mr O'Leary predicted the proposal will not come into law due to a lack of space.
Speaking to the business news on RTE's Morning Ireland, he said: 'We're flying largely full flights, about half the passengers can bring two bags and the other half can only bring one – because that's all that fits in the plane.
'We're already struggling with that amount of baggage.
'That's one of the reasons we are so aggressive about eliminating the scourge of passengers with excess baggage.'
Mr O'Leary said more than 99.9% of passengers comply with baggage rules, with 'sizers' located within the airport.
He said: 'We are happy to incentivise our (staff) with a share of those excess baggage fees, which we think will decline over the coming year or two.'
The chief executive added: 'It is about 1.50 euro per bag – and we're thinking of increasing it, so we eliminate it.'
Meanwhile, Mr O'Leary predicted that US President Donald Trump will 'chicken out' of introducing increased tariffs for Europe on August 1.
Asked if he anticipated tariffs applying to Boeing aircraft being delivered to the airline, he said: 'Trump will probably chicken out again, I suspect the August 1 will get moved to September or October.
'We have taken delivery of five aircraft in the first quarter but no tariffs applied to those aircraft
'There is a risk of tariffs being introduced by the Europeans or the Americans in some tit-for-tat in August, September or October – but Boeing will have to pay those tariffs.'
Mr O'Leary said Ryanair would work with Boeing to ensure no tariffs are applied to commercial aircraft, which he said would be bad for the manufacturer's exports to Europe as well as Airbus's sales to the US – as well as the Irish aircraft leasing industry.
He added: 'There's increasing optimism, though, in Washington that commercial aircraft will be exempt from any tariffs – if Trump ever gets around to actually imposing tariffs.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth
The global cell and gene therapy supply chain software market is set to expand from USD 0.27 billion in 2025 to USD 1.32 billion by 2035, at a CAGR of 15.2%. Driven by demand for advanced therapies, the market is enhanced by cloud-based technologies and key players like Azenta Life Sciences and Lonza. Cell and Gene Therapy Supply Chain Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to offering. The global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in 2025, to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, to 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies. The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems. Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users. The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023. Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years. Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future. The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including process component, type of software, mode of deployment, scale of operation and key geographical regions. Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as type of software, key features, application area, mode of deployment, scale of operation, regulatory guidelines followed and type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and most active players based on the number of software solutions offered. Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as developer strength and product portfolio strength. Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on company overviews, software solutions portfolio, financial information, recent developments and an informed future outlook. Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings. Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements. Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain. Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs. Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth. Sample Players in the Cell and Gene Therapy Supply Chain Software Market, Profiled in the Report Include: Azenta Life Sciences Biocair BioLife Solutions CareDx Cryoport Lonza NMDP BioTherapies TraceLink TrakCel Veeva Systems Emerson LabVantage Solutions Marken MasterControl QuickSTAT Siemens Stafa Cellular Therapy Steiner STEMSOFT Software TECHNIDATA Thermo Fisher Scientific KEY QUESTIONS ANSWERED IN THIS REPORT How many companies are currently engaged in this market? Which are the leading companies in this market? What kind of partnership models are commonly adopted by industry stakeholders? What are the factors that are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. ADDITIONAL BENEFITS Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell and Gene Therapy Supply Chain CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
VW's Skoda posts 12% profit rise in H1 as electric sales grow
PRAGUE (Reuters) -Skoda Auto, a Volkswagen unit, increased the share of electric vehicles in its sales mix in the first half of the year and posted a nearly 12% rise in operating profit to 1.3 billion euros ($1.52 billion), it said on Monday. The Czech carmaker's revenue for the first six months rose nearly 12% year on year to 15.1 billion euros. Deliveries were up 14% to 509,400 vehicles in the period. Around 23% of those deliveries were either fully electric or plug-in hybrid models, up from 9.4% in the first half of last year, the company said. Chief Executive Klaus Zellmer said customers had placed more than 120,000 orders for Skoda's all-electric Enyaq and Elroq models by the end of June, highlighting progress in its electrification strategy. European automakers have booked multi-billion-euro losses and issued profit warnings as they struggle to handle competition from China, U.S. import tariffs, and EU regulations aimed at speeding up the EV transition. "Sales relative to the overall market performance, we are doing good," Zellmer told journalists in a video conference. While overall car sales have fallen in Europe this year, sales of electric vehicles - a priority segment for companies like Skoda Auto - have been rising. Zellmer said the company sees big potential with the new Epiq, an electric SUV priced at 25,000 euros that will target entry-level consumers. It plans to launch the Epiq in the first half of 2026. "We put a lot of hope or I would even say ... expectation on that car," he said. "Our current rate of electrified drive train sales ... has to go up." In the European market, Skoda delivered 409,100 vehicles to customers, an increase of nearly 11% that outperformed the overall market and was underpinned by the sales of 72,000 electric vehicles and 21,400 plug-in hybrids, the company said. Skoda also achieved record results in India where it delivered 33,000 vehicles, representing year-on-year growth of 108%, the company said. ($1 = 0.8527 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Explainer-Why Big Alcohol needs US tariff relief in five charts
By Emma Rumney and Jessica DiNapoli LONDON/NEW YORK (Reuters) -European Union wine and spirits producers could emerge among the few winners of a EU-U.S. trade deal agreed at the weekend that some European officials consider unbalanced. The high-level agreement, which imposes a 15% baseline duty for most EU goods entering the United States, is set to include tariff exemptions for some agricultural products, still to be hammered out. Alcoholic beverages could be among those, according to trade and industry officials. "We are optimistic that in the days ahead this positive meeting and agreement will lead to a return to zero-for-zero tariffs for U.S. and EU spirits products," Distilled Spirits Council President and CEO Chris Swonger said in a statement in response to the U.S.-EU agreement. On Monday, French Trade Minister Laurent Saint Martin also said he expected the spirits sector to be exempted from U.S. tariffs. If confirmed, an exemption would offer a lifeline to alcohol players including the world's biggest spirits maker, Diageo, Pernod Ricard, Remy Cointreau and Campari, all of which are very exposed to vast U.S. market and whose profits have already taken a big hit as consumers spend less on drink. Shares in Pernod, Diageo and Campari initially rose in early trade. But they stood 1.3%, 0.4% and 0.3% lower by 0707 GMT. Shares in Remy fell 2.2%. Alcohol is among the EU's top exports to the United States, worth about 9 billion euros ($10.5 billion) in 2024, according to Eurostat data, with certain products like Remy Martin cognac and champagne required to be produced in specific European regions. About one-third of all exports of Irish whiskey such as Pernod Ricard's Jameson are destined for the United States. Earlier in July, President Donald Trump had threatened a crippling 30% tariff that some industry experts said could stop flows of certain EU goods towards the United States. The United States accounts for about 18% of exports for another exclusively French product, champagne. Of all exports of cognac from its namesake region in France, about 43% end up in the United States. LVMH owns Hennessy Cognac. Remy Cointreau, which makes more than 70% of its sales from French-made cognac, is among the alcohol makers hit hardest by tariffs. It has pegged the hit from tariffs imposed globally at about 45 million euros. For cognac makers, the U.S. tariffs represent a fresh challenge after producers of the drink managed this month to avert the threat of duties of up to around 35% from China. For Spanish and Italian wines, around 14% and 24% of total exports, respectively, are sold in the United States. Beer brewers and makers of popular ready-to-drink cocktails will, however, continue to face tariffs on imported aluminum they may use for cans. Under the EU-U.S. deal struck on Sunday, Washington will continue to impose a levy of 50% on steel and aluminum entering the United States. ($1 = 0.8518 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
